NCT03828643View on ClinicalTrials.gov

Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis

CompletedOBSERVATIONAL
Enrollment

156

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

April 12, 2019

Study Completion Date

April 12, 2019

Conditions
Psoriasis Vulgaris
Interventions
DRUG

Secukinumab

Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.

DRUG

Secukinumab

Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.

Trial Locations (1)

37126

University of Verona, Verona

All Listed Sponsors
lead

Universita di Verona

OTHER

NCT03828643 - Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis | Biotech Hunter | Biotech Hunter